Filed by Bowne Pure Compliance
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2008

IMARX THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

         
Delaware   0001-33043   86-0974730
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
1730 East River Road, Suite 200, Tucson, AZ
   85718-5893
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (520) 770-1259

 
 
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.” On March 31, 2008, we issued a press release announcing our operating results for the fourth quarter and year ended 2007. The text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

 On March 31, 2008, the Registrant also announced that it had received a going concern qualification from Ernst & Young LLP, its independent registered public accounting firm, in connection with the filing of its Annual Report on Form 10-K filed on March 31, 2008.  A copy of the press release is attached to this report as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

     
99.1
  Press Release issued by ImaRx Therapeutics, Inc. on March 31, 2008.

 

2

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 31, 2008

IMARX THERAPEUTICS, INC.

/s/ KEVIN ONTIVEROS                                
By: Kevin Ontiveros
Vice President, Legal Affairs,
General Counsel and Secretary

 

3

 

3

 

EXHIBIT INDEX

         
Exhibit Number       Description
 
        
99.1
      Press Release issued by ImaRx Therapeutics, Inc. on March 31, 2008.

4

 

4